Lemaitre Vascular ( (LMAT) ) has released its Q3 earnings. Here is a breakdown of the information Lemaitre Vascular presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
LeMaitre Vascular, Inc., a company specializing in the development, manufacturing, and marketing of vascular devices and implants, operates within the medical device industry, focusing on solutions for peripheral vascular disease.
In its Q3 2025 financial results, LeMaitre Vascular reported a notable increase in sales and profitability, alongside the announcement of a quarterly dividend. The company highlighted a significant sales growth driven by its grafts and shunts products, with a particular boost from the international launch of Artegraft.
Key financial metrics for Q3 2025 include an 11% increase in sales to $61 million, a gross margin of 75.3%, and a 54% rise in operating income to $20.3 million. The company’s diluted earnings per share also saw a 54% increase to $0.75. Additionally, the company’s cash position improved significantly, with an increase of $23.6 million to $343.1 million. Regional sales growth was strong, with EMEA sales up 18%, Americas up 10%, and APAC up 4%.
Looking forward, LeMaitre Vascular’s management remains optimistic, projecting continued sales and profit growth for the remainder of 2025. The company plans to further invest in its sales force, expand international offices, and pursue regulatory approvals, reflecting a positive outlook for sustained growth and expansion.